The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | The potential value of AI for individuals with CH: improving risk stratification
Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, comments on the potential of artificial intelligence (AI) in personalized medicine for individuals with clonal hematopoiesis (CH), highlighting that AI can help to identify patients at higher risk of developing myeloid malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
